Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| CTI BioPharma Corporation | CTIC | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 9.09 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 9.09 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 4.74 - 9.10 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 9.09 | USD |
CTI BioPharma Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 1.20B | - | - | - | -24.32 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
CTI BioPharma News
| Date | Time | Source | News Article |
|---|---|---|---|
| 7/06/2023 | 15:15 | Edgar (US Regulatory) | Form 15-12G - Securities registration termination [Section.. |
| 6/29/2023 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 6/28/2023 | 17:26 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 6/28/2023 | 12:51 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of.. |
| 6/24/2023 | 05:51 | PR Newswire (US) | Sobi successfully completes tender offer for all outstanding.. |
| 6/24/2023 | 05:49 | PR Newswire (US) | Sobi successfully completes tender offer for all outstanding.. |
| 5/30/2023 | 15:35 | PR Newswire (US) | CTI BioPharma Announces Cancellation of its 2023 Annual.. |
| 5/10/2023 | 00:06 | PR Newswire (US) | Sobi to Acquire CTI BioPharma |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CTIC Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 4.80 | 9.10 | 4.74 | 8.94 | 8,555,071 | 4.29 | 89.38% |
| 3 Years | 2.27 | 9.10 | 1.43 | 5.33 | 3,381,124 | 6.82 | 300.44% |
| 5 Years | 0.95 | 9.10 | 0.62 | 4.74 | 2,144,894 | 8.14 | 856.84% |
CTI BioPharma Description
| CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under pipeline include PIXUVRI, and Pacritinib. PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis. |
